Q-omics provides the consensus-scored STK38 profile across patient tissues and cancer cell-line models. STK38 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STK38 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, STK38 RNA expression shows 20,408 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where STK38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK38 survival associations across molecular data types. STK38 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK38 RNA expression–survival associations across cancer types. High STK38 expression shows unfavorable associations in ACC, MESO, LGG and LIHC, but favorable associations in HNSC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STK38 RNA expression.
This table summarizes STK38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STK38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK38 shows lower tumor expression in KICH and higher tumor expression in KIRP, LUAD, LUSC, LIHC and UCEC. The KICH box plot shows higher STK38 RNA expression in normal versus tumor tissue (log2 FC = −1.764, t-test p < 0.001).
This table shows molecular features associated with STK38 in patient tissues and cancer cell lines. In patient samples, STK38 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STK38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
